SHRXF (Sharp Therapeutics) Other Long Term Assets: $0.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHRXF Sharp Therapeutics Corp SHRXF
12 GF Score
Price $0.57
View Full Analysis

What is Sharp Therapeutics Other Long Term Assets?

Sharp Therapeutics SHRXF 12 Other Long Term Assets is $0.02 Mil as of Jun. 2026. GuruFocus rates SHRXF with a GF Score™ of 12/100.

Sharp Therapeutics's other long-term assets for the quarter that ended in Jun. 2026 was $0.02 Mil.

Sharp Therapeutics's quarterly other long-term assets increased from Sep. 2025 ($0.02 Mil) to Dec. 2025 ($0.02 Mil) but then stayed the same from Dec. 2025 ($0.02 Mil) to Jun. 2026 ($0.02 Mil).

Sharp Therapeutics's annual other long-term assets increased from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.02 Mil) but then declined from Dec. 2024 ($0.02 Mil) to Dec. 2025 ($0.02 Mil).

Sharp Therapeutics Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Other Long Term Assets Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Other Long Term Assets
0.02 0.02 0.02

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02
SHRXF
12GF Score
Sharp Therapeutics Corp SHRXF
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.02 Mil mean?
Sharp Therapeutics (SHRXF) has a Other Long Term Assets of $0.02 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Other Long Term Assets too high?
Sharp Therapeutics' current Other Long Term Assets is $0.02 Mil. Overall, Sharp Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Other Long Term Assets compare to VRTX and REGN?
Sharp Therapeutics' Other Long Term Assets of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Other Long Term Assets is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (SHRXF) has a current Other Long Term Assets of $0.02 Mil. The current Other Long Term Assets is $0.02 Mil. Sharp Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Sharp Therapeutics (SHRXF), the current Other Long Term Assets is $0.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
12GF Score

Get the complete analysis for SHRXF

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price